People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Faraday Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $115.5M | $830.5M | 2014 |
Brian Blackman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Blackman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Robert Nelsen | 1 | 22 |
| Terrance McGuire | 1 | 9 |
| Thomas King | 1 | 6 |
| Paulina Hill | 1 | 5 |
| Stephen Hill | 1 | 3 |
| Mark Roth | 1 | 3 |
| Lawrence Gozlan | 1 | 3 |
| Simon Tulloch | 1 | 1 |
| Patrick Rock | 1 | 1 |
| Ronald Kierpa | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.